Imaging Microglial Activation in PTSD with PET
使用 PET 对 PTSD 中的小胶质细胞激活进行成像
基本信息
- 批准号:10004712
- 负责人:
- 金额:$ 75.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2022-10-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAmericanAmygdaloid structureAnhedoniaAnxietyArousalAttentionBindingBlood - brain barrier anatomyBrainBrain imagingClinicalClinical assessmentsDataDiagnosisDimensionsEndotoxinsEscherichia coliFunctional disorderHealthHippocampus (Brain)HormonesHumanHydrocortisoneImageImmuneImmune systemImpaired cognitionIndividualInflammationInflammatoryInjuryLeadLipopolysaccharidesMeasuresMediatingMediator of activation proteinMicrogliaMoodsNerve DegenerationNeuraxisNeurocognitiveNeurodegenerative DisordersNeuroimmuneNeuroimmune systemNeuroimmunomodulationNeuronal DysfunctionPathologyPeripheralPharmacologyPlayPositron-Emission TomographyPost-Traumatic Stress DisordersProteinsPsychopathologyPublic HealthQuality of lifeRoleSeveritiesStressStress TestsSymptomsSyndromeTNF geneTraumaVentral StriatumVerbal LearningVirusanxiety symptomsanxiousbaseblood-based biomarkercytokinefrontal lobefunctional disabilityin vivoinflammatory markerinsightmood symptomnegative affectneuroinflammationnovelphysical conditioningpotential biomarkerpre-clinicalpsychologicpsychological distressradiotracerreduce symptomsrepairedresponsestress related disorderstressorsymptomatologytargeted treatmenttrauma exposure
项目摘要
Project Summary
Nearly 9 in 10 Americans will be exposed to trauma in their lifetime and 1 in 10 will develop post-traumatic
stress disorder (PTSD), which is characterized by elevated threat (e.g., intrusions, anxious arousal), loss (e.g.,
anhedonia, negative affect) and neurocognitive (e.g., verbal learning, attention) symptoms. Individuals with
PTSD have elevated rates of physical health conditions, as well as functional impairment, with loss symptoms
in particular contributing to decreased quality of life. The immune system is responsible for maintaining health,
which includes mounting a response to physical (e.g., virus, injury) and psychological (e.g., stress) insults, as
well as modulating the progression of neurodegenerative disorders such as Alzheimer’s disease. All of these -
physical health conditions, psychological distress, and neurodegenerative disorders - are more prevalent in
individuals with than without PTSD. There are peripheral immune system abnormalities in PTSD; however, no
known study has evaluated the role of the neuroimmune system in PTSD. In the healthy immune system, the
response of the central nervous system to an insult or damage is mediated by the activation of microglia, which
carry out repair functions. However, excessive activation can lead to neuronal dysfunction and damage
through the release of inflammatory cytokines and stress hormones, and may contribute to neurodegeneration,
such as that found in individuals with PTSD. When microglia are activated, there is a robust increase in the
expression of translocator protein (TSPO). Positron emission tomography (PET) radiotracers such as
[11C]PBR28, which bind to TSPO, can therefore be used to measure levels of activated microglia in vivo. In
addition to measuring levels of activated microglia in individuals with PTSD (vs. controls), we can also
challenge the immune system by administering E. Coli lipopolysaccharide (LPS), a potent immune activator
and measure increases in activated microglia within subject. We have recently demonstrated robust LPS-
induced increases in activated microglia, and concomitant increases in peripheral inflammatory cytokines, and
associated mood, anxiety, and neurocognitive symptoms in humans. In the proposed study, we will
systematically evaluate the relationship between “neuroinflammation”, as assessed with [11C]PBR28 and PET,
and the expression of threat, loss, and neurocognitive symptoms in 80 trauma-exposed individuals presenting
with the full dimensional spectrum of PTSD symptoms. Specifically, we will (1) determine whether individuals
with PTSD have higher levels of activated microglia compared to trauma-exposed controls; (2) use a novel
neuroimmune “stress test” to determine whether individuals with PTSD have a dysfunctional neuroimmune
response to systemic administration of LPS; and (3) determine the role of activated microglia in mediating the
relationship between peripheral inflammatory markers (e.g., TNF-α), and trauma-related symptoms to discover
potential biomarkers of PTSD. Results of this study will yield insight into novel, mechanism-based, and
treatable neuroimmune mechanisms implicated in PTSD and related syndromes.
项目总结
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Accuracy of arterial [18F]-Fluorodeoxyglucose uptake quantification: A kinetic modeling study.
动脉[18F]-氟脱氧葡萄糖摄取定量的准确性:动力学模型研究。
- DOI:10.1007/s12350-020-02055-x
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Toczek,Jakub;Wu,Jing;Hillmer,AnselT;Han,Jinah;Esterlis,Irina;Cosgrove,KellyP;Liu,Chi;Sadeghi,MehranM
- 通讯作者:Sadeghi,MehranM
Acute neuroimmune stimulation impairs verbal memory in adults: A PET brain imaging study.
- DOI:10.1016/j.bbi.2020.09.027
- 发表时间:2021-01
- 期刊:
- 影响因子:0
- 作者:Woodcock EA;Hillmer AT;Sandiego CM;Maruff P;Carson RE;Cosgrove KP;Pietrzak RH
- 通讯作者:Pietrzak RH
Sex differences in progestogen- and androgen-derived neurosteroids in vulnerability to alcohol and stress-related disorders.
- DOI:10.1016/j.neuropharm.2021.108499
- 发表时间:2021-04-01
- 期刊:
- 影响因子:4.7
- 作者:Peltier MR;Verplaetse TL;Mineur YS;Gueorguieva R;Petrakis I;Cosgrove KP;Picciotto MR;McKee SA
- 通讯作者:McKee SA
FDG PET imaging of vascular inflammation in post-traumatic stress disorder: A pilot case-control study.
创伤后应激障碍中血管炎症的 FDG PET 成像:一项试点病例对照研究。
- DOI:10.1007/s12350-019-01724-w
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Toczek,Jakub;Hillmer,AnselT;Han,Jinah;Liu,Chi;Peters,Dana;Emami,Hamed;Wu,Jing;Esterlis,Irina;Cosgrove,KellyP;Sadeghi,MehranM
- 通讯作者:Sadeghi,MehranM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kelly P Cosgrove其他文献
Kelly P Cosgrove的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kelly P Cosgrove', 18)}}的其他基金
Enhancing dissemination and career development in sex and gender translational science in alcohol use
加强酒精使用中性和性别转化科学的传播和职业发展
- 批准号:
10821828 - 财政年份:2023
- 资助金额:
$ 75.33万 - 项目类别:
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
研究酒精使用障碍中的 Mu:Kappa 阿片受体失衡
- 批准号:
10731950 - 财政年份:2023
- 资助金额:
$ 75.33万 - 项目类别:
PROJECT 2: Imaging sex differences in stress-related neurochemical mechanisms of alcohol use disorders
项目 2:酒精使用障碍的压力相关神经化学机制的性别差异成像
- 批准号:
10357883 - 财政年份:2020
- 资助金额:
$ 75.33万 - 项目类别:
Translational Alcohol Research Program (TARP)
转化酒精研究计划 (TARP)
- 批准号:
10621155 - 财政年份:2020
- 资助金额:
$ 75.33万 - 项目类别:
PROJECT 2: Imaging sex differences in stress-related neurochemical mechanisms of alcohol use disorders
项目 2:酒精使用障碍的压力相关神经化学机制的性别差异成像
- 批准号:
10599823 - 财政年份:2020
- 资助金额:
$ 75.33万 - 项目类别:
Translational Alcohol Research Program (TARP)
转化酒精研究计划 (TARP)
- 批准号:
10396641 - 财政年份:2020
- 资助金额:
$ 75.33万 - 项目类别:
Translational Alcohol Research Program (TARP)
转化酒精研究计划 (TARP)
- 批准号:
10159175 - 财政年份:2020
- 资助金额:
$ 75.33万 - 项目类别:
Imaging Microglial Activation in PTSD with PET
使用 PET 对 PTSD 中的小胶质细胞激活进行成像
- 批准号:
9309643 - 财政年份:2017
- 资助金额:
$ 75.33万 - 项目类别:
Imaging Molecular Mechanisms of Tobacco Smoking Withdrawal
戒烟的分子机制成像
- 批准号:
9841911 - 财政年份:2016
- 资助金额:
$ 75.33万 - 项目类别:
Imaging Molecular Mechanisms of Tobacco Smoking Withdrawal
戒烟的分子机制成像
- 批准号:
9232117 - 财政年份:2016
- 资助金额:
$ 75.33万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 75.33万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 75.33万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 75.33万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 75.33万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 75.33万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 75.33万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 75.33万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 75.33万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 75.33万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 75.33万 - 项目类别: